The U.S. FDA has approved a first of its kind drug from Shire to treat patients suffering from a rare disease, hereditary angioedema (HAE), that causes swelling.
The drug, Takhzyro, is expected to bring in blockbuster sales for Shire. The approval is important to Japan’s Takeda Pharma, as it prepares to buy Shire for $62 billion.
Takhzyro is the only monoclonal antibody (mAb) that provides targeted inhibition of plasma kallikrein, an enzyme which is chronically uncontrolled in people with HAE, to help prevent attacks.
Read the press release
[javascriptSnippet]